Labcorp’s expanded DPYD Genotyping test now detects all Tier 1 and Tier 2 variants to identify the roughly 9% of cancer patients at elevated risk for severe fluoropyrimidine toxicity. The update aligns with FDA Boxed Warnings and NCCN and CPIC guidelines, bolstering Labcorp’s pharmacogenomics oncology portfolio.
Labcorp expanded its DPYD Genotyping test to include all Tier 1 and Tier 2 gene variants recommended by the Association for Molecular Pathology, enabling detection of mutations that impair metabolism of fluoropyrimidine drugs such as 5-FU and capecitabine.
Approximately 9% of patients carry DPYD variants that increase risks of severe or life-threatening chemotherapy toxicity, contributing to around 1,300 US deaths annually from 5-FU; the expanded test aligns with FDA Boxed Warnings and updated NCCN and CPIC guidelines for dosing adjustments.
Building on a DPYD testing service launched in 2006, this expansion strengthens Labcorp’s pharmacogenomics offerings across oncology and other specialties, supporting more personalized cancer care and potentially driving increased clinical adoption and revenue growth.
